Related Experiment Video
Updated: Mar 30, 2026

05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.6K
Teaching Video NeuroImages: Feeding dystonia in chorea-acanthocytosis
Martin Paucar1, Per-Åke Lindestad2, Ruth H Walker2
1From the Departments of Neurology (M.P., P.S.) and Otolaryngology (P.-Å.L.), Karolinska University Hospital; Department of Clinical Neuroscience (N.P., P.S.), Karolinska Institutet, Stockholm, Sweden; Department of Neurology (R.H.W.), James J. Peters Veterans Medical Affair Center, Bronx; and Department of Neurology (R.H.W.), Mount Sinai School of Medicine, New York, NY. martin.paucar-arce@karolinska.se.
Neurology
|November 11, 2015
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K

